Strategic expansion Ionetix is rapidly expanding its Delta Township facility with a second cyclotron and an advanced isotope processing lab, backed by significant funding and a headcount increase. This signals growing capacity to serve more PET programs nationwide and align with potential customers seeking reliable isotope supply and on-site cyclotron capabilities.

Alpha therapy momentum The company is actively advancing targeted alpha therapy through collaborations to produce Actinium-225 and support TAT development. This opens opportunities to engage oncology developers, radiopharmaceutical manufacturers, and hospitals seeking next generation radiotherapy isotopes and integrated production solutions.

Pay-by-dose model Ionetix covers installation and ongoing operation costs for cyclotrons and provides N-13 Ammonia via a pay-by-the-dose model. This business model reduces customer capital barriers, enabling outreach to PET programs that require reliable isotope supply without upfront infrastructure investments.

Strategic partnerships Recent partnerships with Lilly and AlfaRim position Ionetix as a key supplier and collaborator in isotopes ready for commercial development. There are clear cross-sell and co-development opportunities with pharma, research institutes, and deep-tech partners pursuing new radiopharmaceuticals and diagnostic/therapeutic workflows.

Financial health signal Publicized financing rounds and a formal go-public transaction indicate strong investor confidence and available capital for scale-up. Sales teams can leverage this to approach larger PET centers and academic medical centers with a credible growth narrative and expanded service portfolio.